TABLE 2.

Patient characteristics at baseline

Women, n (%)	95 (54)
Age, years, median (IQR) [range]	36 (29‐48) [18‐70]
Age at diagnosis, years, median (IQR) [range]	33 (22‐42) [3‐68]
Crohn's disease, n (%)	97 (55)
Ulcerative colitis, n (%)	78 (45)
Body weight, kg, median (IQR) [range]	69 (60‐80) [43‐118]
Immunomodulators
Pre‐treatment, n (%)	147 (84)
During treatment, n (%)	80 (46)
Corticosteroids
Pre‐treatment, n (%)	106 (61)
During treatment, n (%)	71 (41)
Crohn's disease activity index (n = 96), median (IQR) [range] Full Mayo clinic score (n = 73), median (IQR) [range]	283 (249‐333) [222‐446] 8 (7‐9) [4‐11]
Haemoglobin, g/L, median (IQR) [range]	128 (117‐139) [43‐170]
Platelet count, ×109/L, median (IQR) [range]	295 (243‐366) [43‐698]
White blood cell count, ×109/L, median (IQR) [range]	7.1 (5.6‐9.1) [2.7‐43]
Albumin, g/L, median (IQR) [range]	44 (40‐46) [28‐54]
C‐reactive protein, mg/L, median (IQR) [range]	3.2 (1.2‐7.9) [0.2‐89.4]
Faecal calprotectin, mg/kg, median (IQR) [range]	749 (265‐1576) [10‐6913]
Neutralising antibodies during treatment, n (%)	58 (33)

Part 1 of the study (n = 44, all with Crohn's disease) was designed to find the optimal dose of subcutaneous CT‐P13. Part 2 (n = 131, 53 with Crohn's disease, 78 with ulcerative colitis) of the study was designed to demonstrate non‐inferiority in pharmacokinetics between subcutaneous and intravenous CT‐P13.